Associated Papers
Pathway-based, reaction-specific annotation of disease variants for elucidation of molecular phenotypes.
Orlic-Milacic M et al.
Database : the Journal of Biological Databases and Curation, 2024
Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma.
Liu T et al.
Cold Spring Harbor Molecular Case Studies, 2021
Landscape of drug-resistance mutations in kinase regulatory hotspots.
Kim P et al.
Briefings in Bioinformatics, 2021
Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation.
Patil K et al.
Proceedings of the National Academy of Sciences of the United States of America, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Computational algorithms for in silico profiling of activating mutations in cancer.
Jordan EJ et al.
Cellular and Molecular Life Sciences : Cmls, 2019
Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase.
Johnson TW et al.
Acs Medicinal Chemistry Letters, 2018
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
Guan J et al.
Disease Models & Mechanisms, 2016
Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies.
Mossé YP
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
Kopetz S et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2015
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
Bresler SC et al.
Cancer Cell, 2014
Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.
Chand D et al.
Disease Models & Mechanisms, 2013
Oncogenic anaplastic lymphoma kinase (ALK) mutation in neuroblastomas and other pediatric tumors.
Kwon MJ et al.
Pathology, Research and Practice, 2011
Emerging importance of ALK in neuroblastoma.
Azarova AM et al.
Seminars in Cancer Biology, 2011
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
Lee CC et al.
The Biochemical Journal, 2010
Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.
Bossi RT et al.
Biochemistry, 2010
Genetics and genomics of neuroblastoma.
Capasso M et al.
Cancer Treatment and Research, 2010
Anaplastic lymphoma kinase: signalling in development and disease.
Palmer RH et al.
The Biochemical Journal, 2009
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.
Webb TR et al.
Expert Review of Anticancer Therapy, 2009
Identification of ALK as a major familial neuroblastoma predisposition gene.
Mossé YP et al.
Nature, 2008